Cytokinetics (NASDAQ:CYTK) Given New $100.00 Price Target at Leerink Partners

Cytokinetics (NASDAQ:CYTK) had its price target cut by Leerink Partners from $103.00 to $100.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners‘s target price suggests a potential upside of 80.64% from the company’s current price.

CYTK has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a research report on Thursday, October 15th. Citizens Jmp boosted their target price on Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Barclays boosted their target price on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 20th. Finally, Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a report on Tuesday, September 1st. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $106.33.

Cytokinetics Price Performance

Shares of CYTK traded down $8.24 during midday trading on Thursday, reaching $55.36. The stock had a trading volume of 4,345,430 shares, compared to its average volume of 2,102,162. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -7.64 and a beta of 0.45. The company’s fifty day simple moving average is $66.63 and its two-hundred day simple moving average is $70.05. Cytokinetics has a 1-year low of $54.30 and a 1-year high of $88.31.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.06. The firm had revenue of $47.56 million for the quarter, compared to analyst estimates of $41.88 million. The business’s revenue for the quarter was up 2356.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.55) EPS. On average, sell-side analysts forecast that Cytokinetics will post -5.97 earnings per share for the current year.

Insider Activity

In related news, EVP Fady Malik sold 3,500 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $62.93, for a total value of $220,255.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares of the company’s stock, valued at $9,685,052.86. This represents a 2.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $62.81, for a total value of $471,075.00. Following the transaction, the chief executive officer owned 278,544 shares in the company, valued at $17,495,348.64. This represents a 2.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 180,926 shares of company stock valued at $12,510,340. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently modified their holdings of CYTK. New York Life Investment Management LLC grew its position in shares of Cytokinetics by 29.3% during the third quarter. New York Life Investment Management LLC now owns 19,047 shares of the biopharmaceutical company’s stock worth $1,255,000 after acquiring an additional 4,316 shares during the last quarter. Retirement Systems of Alabama increased its holdings in shares of Cytokinetics by 2.1% in the 3rd quarter. Retirement Systems of Alabama now owns 143,395 shares of the biopharmaceutical company’s stock valued at $9,451,000 after acquiring an additional 2,969 shares during the period. Allspring Global Investments Holdings LLC raised its position in Cytokinetics by 4.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,833 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 302 shares during the last quarter. Candriam S.C.A. raised its position in Cytokinetics by 39.3% in the 3rd quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company’s stock valued at $40,841,000 after purchasing an additional 174,320 shares during the last quarter. Finally, Ethic Inc. raised its position in Cytokinetics by 17.3% in the 3rd quarter. Ethic Inc. now owns 22,240 shares of the biopharmaceutical company’s stock valued at $1,466,000 after purchasing an additional 3,275 shares during the last quarter.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: For Q3 2026, Cytokinetics reported a loss of $1.37 per share, narrower than the $1.43 consensus loss, while revenue of $47.56 million topped estimates of $41.88 million. Revenue was up sharply year over year, and the loss narrowed from $2.55 per share a year earlier. Cytokinetics Q3 Loss Narrows, Revenue Rises
• Positive Sentiment: A valuation commentary argued CYTK could be 41% undervalued, citing the strong quarter and aficamten data. That is an analyst-style valuation view, not a guarantee of future performance. Cytokinetics Could Be 41% Undervalued
• Neutral Sentiment: MYQORZO adoption is a key commercial factor for investors to watch; its uptake could affect Cytokinetics’ future revenue, but the article’s headline does not provide specific sales or adoption figures. How MYQORZO Adoption Will Impact Cytokinetics Stock
• Negative Sentiment: The company remains loss-making despite beating estimates, leaving investors focused on whether product growth can translate into improved profitability. Cytokinetics Q3 Results

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.